Free Trial

CNS Pharmaceuticals Q1 2023 Earnings Report

CNS Pharmaceuticals logo
$1.10 -0.03 (-2.65%)
As of 04:00 PM Eastern

CNS Pharmaceuticals EPS Results

Actual EPS
-$6,475.00
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

CNS Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

CNS Pharmaceuticals Announcement Details

Quarter
Q1 2023
Time
N/A

Conference Call Resources

Remove Ads

CNS Pharmaceuticals Earnings Headlines

CNS Pharmaceuticals sees cash runway into 1Q26
FBI Warns: Wave Of Retiree Cyber Hacks Coming In 2025
Try to think back to the fall of 2008… The pandemic accelerated America's descent into a “no-cash society” by several years…
CNS Pharmaceuticals announces primary analysis of berubicin in GBM
See More CNS Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like CNS Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CNS Pharmaceuticals and other key companies, straight to your email.

About CNS Pharmaceuticals

CNS Pharmaceuticals (NASDAQ:CNSP), a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc., Reata Pharmaceuticals, Inc., Pomeranian Medical University, and The University of Texas M.D. Anderson Cancer Center; and a development agreement with WPD Pharmaceuticals Inc. The company was incorporated in 2017 and is based in Houston, Texas.

View CNS Pharmaceuticals Profile

More Earnings Resources from MarketBeat